Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
May 12, 2023
Genethon’s R&D to be Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 16-20, 2023, in Los Angeles, CA
ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2
April 27, 2023
Crigler-Najjar syndrome: Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy for patients with anti-AAV antibodies
March 6, 2023
Crigler-Najjar Syndrome: Genethon obtains PRIME priority drug status from the EMA for its gene therapy
January 10, 2023
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
October 11, 2022
Genethon’s Latest Research, Including Advances in Gene Editing and AAV Delivery Vectors for Gene Therapy, to be Featured at European Society for Gene and Cell Therapy, Oct. 11-14, 2022
The gene therapy pioneering organization’s scientists will make multiple presentations on research aimed at curing rare diseases.
(read more)September 26, 2022
First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9
Study to treat FKRP-related limb-girdle muscular dystrophy type 2I/R9 represents 30 years of research and is being conducted by Genethon spinout Atamyo Therapeutics.
(read more)September 12, 2022
Genethon to Present Its Latest Gene Therapy Research Advancements in Neuromuscular Diseases at the International Myology 2022 Congress
Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), announced today its scientists will make five oral presentations and display 18 posters of their latest research on neuromuscular diseases at the 7th International… (read more)
May 16, 2022
Genethon’s R&D to be Featured in Multiple Presentations at ASGCT Annual Meeting, May 16-19
April 4, 2022
Genethon Joins U.S. Bespoke Gene Therapy Consortium Dedicated to Finding Treatments for Ultra-Rare Diseases
February 28, 2022
Gene Therapies Continue to Emerge as Effective Treatments for Rare Diseases, But Complex Challenges Remain
To mark International Rare Disease Day, Genethon identifies the most urgent priorities in overcoming these obstacles.
(read more)February 10, 2022
Genethon’s Lentiviral Vector-Based Gene Therapy Demonstrates Long-Term Safety and Efficacy for Wiskott-Aldrich Syndrome
January 6, 2022
Genethon Announces Publication of Results paving the way for Gene Therapy for XLH, a Skeletal Disorder
The AAV-based therapy targets the liver’s hepatocytes to express therapeutic proteins for secretion into the bloodstream and long-lasting treatment of the rare disease.
(read more)October 20, 2021
